Multivariate analysis for relative risk of death
. | Relative risk of death (95% CI) . | P . |
|---|---|---|
| HLA-identical sibling BM | ||
| G-CSF+ within 7 days after transplantation vs no G-CSF* | 1.11 (0.90-1.36) | .35 |
| Age | 1.02 (1.01-1.03) | .004 |
| KPS more than 80* vs less than 80% | 1.34 (1.10-1.64) | .004 |
| Disease stage at transplantation | ||
| Intermediate vs early* | 1.99 (1.57-2.52) | < .001 |
| Advanced vs early* | 2.93 (2.35-3.65) | < .001 |
| HLA-identical sibling PBSCs | ||
| G-CSF+ within 7 days after transplantation vs no G-CSF* | 1.07 (0.84-1.37) | .57 |
| Age | 1.02 (1.01-1.03) | .003 |
| KPS more than 80* vs less than 80% | 1.66 (1.29-2.13) | < .001 |
| Disease stage at transplantation | ||
| Intermediate vs early* | 1.60 (1.14-2.24) | .006 |
| Advanced vs early* | 3.48 (2.64-4.59) | < .001 |
| Matched unrelated donor BM | ||
| G-CSF+ within 7 days after transplantation vs no G-CSF* | 0.83 (0.67-1.03) | .09 |
| Age | 1.02 (1.01-1.03) | .02 |
| KPS more than 80* vs less than 80% | 1.40 (1.09-1.80) | .008 |
| Recipient CMV status, negative vs positive* | 0.69 (0.56-0.87) | .001 |
| Disease stage at transplantation | ||
| Intermediate vs early* | 1.46 (1.11-1.92) | .007 |
| Advanced vs early* | 2.64 (2.04-3.43) | < .001 |
. | Relative risk of death (95% CI) . | P . |
|---|---|---|
| HLA-identical sibling BM | ||
| G-CSF+ within 7 days after transplantation vs no G-CSF* | 1.11 (0.90-1.36) | .35 |
| Age | 1.02 (1.01-1.03) | .004 |
| KPS more than 80* vs less than 80% | 1.34 (1.10-1.64) | .004 |
| Disease stage at transplantation | ||
| Intermediate vs early* | 1.99 (1.57-2.52) | < .001 |
| Advanced vs early* | 2.93 (2.35-3.65) | < .001 |
| HLA-identical sibling PBSCs | ||
| G-CSF+ within 7 days after transplantation vs no G-CSF* | 1.07 (0.84-1.37) | .57 |
| Age | 1.02 (1.01-1.03) | .003 |
| KPS more than 80* vs less than 80% | 1.66 (1.29-2.13) | < .001 |
| Disease stage at transplantation | ||
| Intermediate vs early* | 1.60 (1.14-2.24) | .006 |
| Advanced vs early* | 3.48 (2.64-4.59) | < .001 |
| Matched unrelated donor BM | ||
| G-CSF+ within 7 days after transplantation vs no G-CSF* | 0.83 (0.67-1.03) | .09 |
| Age | 1.02 (1.01-1.03) | .02 |
| KPS more than 80* vs less than 80% | 1.40 (1.09-1.80) | .008 |
| Recipient CMV status, negative vs positive* | 0.69 (0.56-0.87) | .001 |
| Disease stage at transplantation | ||
| Intermediate vs early* | 1.46 (1.11-1.92) | .007 |
| Advanced vs early* | 2.64 (2.04-3.43) | < .001 |
BM indicates bone marrow; G-CSF, granulocyte colony-stimulating factor; KPS, Karnofsky performance status; PBSC, peripheral blood stem cell; and CMV, cytomegalovirus.
Reference group